The value of pharmaceutical R&D projects under uncertainty and drug approval policy

Pharmaceutical R&D projects often have the characteristics of irreversibility on investment, flexibility of investment timing, and uncertainty in cash flows. In this thesis, the real options approach is used as the evaluation tool for these projects and three continuous-time investment models ar...

Full description

Bibliographic Details
Main Author: Wei, Wei
Other Authors: Thijssen, Jacco
Published: University of York 2016
Subjects:
Online Access:https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.721891
id ndltd-bl.uk-oai-ethos.bl.uk-721891
record_format oai_dc
spelling ndltd-bl.uk-oai-ethos.bl.uk-7218912019-01-29T03:20:29ZThe value of pharmaceutical R&D projects under uncertainty and drug approval policyWei, WeiThijssen, Jacco2016Pharmaceutical R&D projects often have the characteristics of irreversibility on investment, flexibility of investment timing, and uncertainty in cash flows. In this thesis, the real options approach is used as the evaluation tool for these projects and three continuous-time investment models are developed. In chapter 4, we discuss the effects of the investment lag and commercialization flexibility on the investment decisions under uncertainty. Chapter 5 examines which organizational structures, the decentralized or centralized pharmaceutical R&D project, are more socially desirable in terms of early investment and higher project value. Chapter 6 considers whether adding a time constraint on the drug development process will increase the investment incentives and how remuneration level will influence the quality of the products, as well as the timing of commercialization.658.5University of Yorkhttps://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.721891http://etheses.whiterose.ac.uk/17815/Electronic Thesis or Dissertation
collection NDLTD
sources NDLTD
topic 658.5
spellingShingle 658.5
Wei, Wei
The value of pharmaceutical R&D projects under uncertainty and drug approval policy
description Pharmaceutical R&D projects often have the characteristics of irreversibility on investment, flexibility of investment timing, and uncertainty in cash flows. In this thesis, the real options approach is used as the evaluation tool for these projects and three continuous-time investment models are developed. In chapter 4, we discuss the effects of the investment lag and commercialization flexibility on the investment decisions under uncertainty. Chapter 5 examines which organizational structures, the decentralized or centralized pharmaceutical R&D project, are more socially desirable in terms of early investment and higher project value. Chapter 6 considers whether adding a time constraint on the drug development process will increase the investment incentives and how remuneration level will influence the quality of the products, as well as the timing of commercialization.
author2 Thijssen, Jacco
author_facet Thijssen, Jacco
Wei, Wei
author Wei, Wei
author_sort Wei, Wei
title The value of pharmaceutical R&D projects under uncertainty and drug approval policy
title_short The value of pharmaceutical R&D projects under uncertainty and drug approval policy
title_full The value of pharmaceutical R&D projects under uncertainty and drug approval policy
title_fullStr The value of pharmaceutical R&D projects under uncertainty and drug approval policy
title_full_unstemmed The value of pharmaceutical R&D projects under uncertainty and drug approval policy
title_sort value of pharmaceutical r&d projects under uncertainty and drug approval policy
publisher University of York
publishDate 2016
url https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.721891
work_keys_str_mv AT weiwei thevalueofpharmaceuticalrdprojectsunderuncertaintyanddrugapprovalpolicy
AT weiwei valueofpharmaceuticalrdprojectsunderuncertaintyanddrugapprovalpolicy
_version_ 1718968784627171328